http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-054770-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| filingDate | 2006-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feb29b1d69ea0d4b4344c137083a4bf4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e10e9cf4ca25c598d57e47a807f594db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b2732c56900db232e918d7548b95ddb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03798399ef15c00228e2826c00ae8f64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3353ef74f5b55b7199a59c2820cfceac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06804fb2083df0d0be05a0d467c109ae |
| publicationDate | 2007-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-054770-A1 |
| titleOfInvention | OXOINDOLES AS INHIBITORS OF KINASES, A METHOD FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR PREPARATION, A GAME OF ELEMENTS THAT USE THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE PROCESSING OF MEDIAIN QUASINES BY MEK. |
| abstract | Oxindoles of the formula (1), its use as activators or inhibitors of protein kinases, a method for its preparation, its use in the preparation of a medicament for the treatment of diseases and its use in the elaboration of a pharmaceutical composition. Claim 1: A compound of the formula (1) wherein X is Ar or Het; R2 is H, A, Ar, (CH2) mCON (R8) 2, (CH2) mCONHAr, S (O) mA, S (O) mAr, NHCOA, NHCOAr, NHSO2A, NHSO2Ar, SO2N (R8) 2, N ( CH2) nC (CH3) 2 (CH2) nN (R8) 2, (CH2) nN (R8) SOmA, (CH2) nN (R8) SOmAr, (CH2) nSOmA, (CH2) nSOmAr or (CH2) nSOmN (R8 )TO; R3, R4, R5, R6, R7 are, independently of each other, H, A, Ar, OR8, SR8, OAr, SAr, N (R8) 2, NHAr, NAr2, Hal, NO2, CN, COR8, COAr , S (O) mA, S (O) mAr, NHCOA, NHCOAr, NHSO2A, NHSO2Ar, SO2N (R8) 2, O (CH2) nN (R8) 2, O (CH2) nNHR8, O (CH2) n-morpholine , O (CH2) n-piperazine, O (CH2) n-pyrrolidine, O (CH2) n-piperidine, O-piperidine, O (CH2) n-oxopiperazine, O (CH2) n-oxomorpholine, O (CH2) n -oxopyrrolidine, O (CH2) nC (CH3) 2 (CH2) nN (R8) 2, N (CH2) nC (CH3) 2 (CH2) nN (R8) 2, O (CH2) nN (R8) SOmA, O (CH2) nN (R8) SOmAr, O (CH2) nN (R8) SOmN (R8) 2A, (CH2) nN (R8) SOmA, (CH2) nN (R8) SOmAr, (CH2) nN (R8) SOmN ( R8) 2A, O (CH2) nSOmA, O (CH2) nSOmAr, O (CH2) nSOmN (R8) A, (CH2) nSOmA, (CH2) nSOmAr or (CH2) nSOmN (R8) A, R8 is H, A or A-Ar; A is a linear or branched alkyl or cycloalkyl that is optionally substituted by Hal, Ar is aryl; Het is heteroaryl; Hal is Cl, Br, I or F; n, p are, independently of each other, 0-5; m is 0-2; with the proviso that one of the residues R2, R3, R4, R5, R6 or R7 is different from H and that the compound 3- (1-amino-2-phenyl-ethylidene) -1-methyl-1,3 is excluded -dihydro-indole-2-one, and the salts, derivatives, prodrugs, solvates and stereoisomers acceptable for physiological use thereof, including all the proportions of mixtures thereof. Claim 12: A method of making a compound according to formula (1), characterized in that, a) an aromatic or heteroaromatic nitrile is reacted according to formula (2) Ns-X-R1-R7 wherein R1 , R7 and X are as defined in claim 1, with a straight or branched chain alcohol according to formula (3) HO-R9 wherein R9 is (CH2) q and q is 1-10; and that the product according to formula (4) wherein R1, R7, R9 and X are as defined in claim 1, is then reacted with a compound according to formula (5), wherein R2, R3, R4, R5 and R6 are as defined in claim 1, or b) a compound of formula (1) is isolated or treated with an acid or a base, to obtain the salt thereof. Claim 27: A set (set of elements), consisting of separate packages of: a) an amount effective for therapeutic use of one or more compounds according to one of claims 1 to 11 and b) an amount effective for therapeutic use of one or more additional pharmaceutically active agents other than the compounds according to one of claims 1 to 11. Claim 28: A process of making a pharmaceutical composition, characterized in that one or more compounds are converted according to one of the claims 1 to 11 and one or more compounds selected from the group consisting of excipients, auxiliaries, adjuvants, diluents, vehicles and pharmaceutically active agents, solids, liquids or semi-liquids, other than the compounds according to one of claims 1 to 11, in a proper dosage form. |
| priorityDate | 2005-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.